Opportunity Information: Apply for RFA HS 20 003
The funding opportunity titled "Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (R01)" (Funding Opportunity Number RFA-HS-20-003) is a discretionary grant program from the Agency for Healthcare Research and Quality (AHRQ). It supports R01 research projects that take a close, evidence-based look at how healthcare delivery systems, individual healthcare professionals, and the U.S. healthcare system overall responded to the COVID-19 pandemic. The emphasis is on studies that are genuinely novel and likely to produce high-impact findings that health leaders, clinicians, and policymakers can use to strengthen preparedness and improve care during future public health emergencies.
AHRQ is looking for research that evaluates the real-world consequences of the COVID-19 response on healthcare performance, especially in areas tied to quality, safety, and value. In practice, that means examining how organizations adapted care processes under crisis conditions, what tradeoffs were made, and how those decisions affected patient outcomes and system functioning. The FOA also highlights interest in the role of primary care practices and primary care professionals during the pandemic, recognizing that primary care often serves as the front door to the health system and may have faced unique challenges related to triage, continuity of chronic disease management, patient communication, and coordination with public health guidance.
A major priority in this announcement is understanding equity impacts. AHRQ specifically calls for work that examines how the COVID-19 response affected socially vulnerable populations and people living with multiple chronic conditions. This includes studying whether emergency changes in care delivery widened or narrowed disparities in access, outcomes, and patient experience, and identifying the system factors that contributed to those results. The goal is to generate actionable lessons about what helped protect vulnerable communities and what failed, so future responses can be designed with equity and resilience in mind.
Another central theme is digital healthcare, with particular attention to the rapid expansion of telehealth during COVID-19. AHRQ is interested in both innovations and challenges that emerged as telehealth scaled quickly, such as changes in workflow, clinician decision-making, patient engagement, privacy considerations, access barriers (for example, broadband or device limitations), and the quality and safety implications of remote care. Studies can focus on how telehealth affected clinical outcomes, utilization patterns, patient and provider experiences, and system costs or efficiency, as well as what models worked best for different populations and conditions.
Methodologically, the FOA strongly encourages multi-method, rapid-cycle research. The expectation is that funded teams will be able to produce and disseminate initial findings within six months after the award is made, and then continue sharing results regularly over the remainder of the project period. This points toward designs that can move quickly while still being rigorous, such as combining quantitative analyses of real-world data with qualitative insights from clinicians, staff, and patients, and using iterative approaches that allow emerging findings to be translated into practical guidance without waiting until the end of the grant.
Eligible applicants are broad and include state governments; special district governments; public and state-controlled institutions of higher education; private institutions of higher education; small businesses; nonprofit organizations (with or without 501(c)(3) status, as long as they are not institutions of higher education); federally recognized Native American tribal governments; tribal organizations other than federally recognized tribal governments; and public housing authorities/Indian housing authorities. The FOA also explicitly names additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions. Foreign organizations and foreign institutions (non-U.S. entities) are not eligible to apply.
Key administrative details from the posting include the activity category of Health (CFDA 93.226), an original closing date of June 15, 2020, and a creation date of May 14, 2020. The award ceiling and expected number of awards are not specified in the provided source information. Overall, the opportunity is designed to quickly generate practical, evidence-based lessons about how U.S. healthcare responded under extreme pressure, what worked, what did not, and how to build a safer, higher-quality, more equitable system going forward.Apply for RFA HS 20 003
- The Agency for Health Care Research and Quality in the health sector is offering a public funding opportunity titled "Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.226.
- This funding opportunity was created on 2020-05-14.
- Applicants must submit their applications by 2020-06-15. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, Special district governments, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same agency: Agency for Health Care Research and Quality
Browse more opportunities from the same category: Health
Next opportunity: Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
Previous opportunity: Competitive Revision Supplements to Existing AHRQ Health Service Research (HSR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HS 20 003
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HS 20 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Clinical Trials in Organ Transplantation in Children and Adults (CTOT-CA) (U01 Clinical Trial Optional) Apply for RFA AI 20 029 Funding Number: RFA AI 20 029 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implementation Research to Improve Case Finding, Cascade Screening, and Treatment for Familial Hypercholesterolemia (FH) (R61/R33 Clinical Trial Required) Apply for RFA HL 22 006 Funding Number: RFA HL 22 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed) Apply for RFA RM 20 019 Funding Number: RFA RM 20 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Noninvasive mTBI Tool RFI Apply for HU000120R0047 Funding Number: HU000120R0047 Agency: Uniformed Services Univ. of the Health Sciences Category: Health Funding Amount: Case Dependent |
| IDeA Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54 - Clinical Trial Optional) Apply for PAR 20 175 Funding Number: PAR 20 175 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mucosal Immunology Studies Team (MIST) (U01 Clinical Trial Not Allowed). Apply for RFA AI 20 027 Funding Number: RFA AI 20 027 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Competitive Revision Supplements to Existing AHRQ Patient Centered Outcomes Research (PCOR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional) Apply for PA 20 072 Funding Number: PA 20 072 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed) Apply for PAR 20 178 Funding Number: PAR 20 178 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed) Apply for PAR 20 177 Funding Number: PAR 20 177 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) Disease Modifying Therapies for Chronic Lung Diseases (U24 Clinical Trial Required - Infrastructure) Apply for RFA HL 21 012 Funding Number: RFA HL 21 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required) Apply for RFA HL 21 013 Funding Number: RFA HL 21 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Frontier Health Markets (FHM) Apply for RFI 20 GH FHM 01 Funding Number: RFI 20 GH FHM 01 Agency: Agency for International Development Category: Health Funding Amount: $250,000,000 |
| Research Program Award (R35 Clinical Trial Optional) Apply for RFA NS 20 030 Funding Number: RFA NS 20 030 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required) Apply for PAR 20 209 Funding Number: PAR 20 209 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed) Apply for PAR 20 210 Funding Number: PAR 20 210 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional) Apply for RFA RM 20 011 Funding Number: RFA RM 20 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional) Apply for RFA RM 20 012 Funding Number: RFA RM 20 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required) Apply for PAR 20 215 Funding Number: PAR 20 215 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) Apply for PAR 20 217 Funding Number: PAR 20 217 Agency: National Institutes of Health Category: Health Funding Amount: $1,050,000 |
| NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required) Apply for PAR 20 218 Funding Number: PAR 20 218 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HS 20 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
